HRP20180506T1 - Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela - Google Patents

Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela Download PDF

Info

Publication number
HRP20180506T1
HRP20180506T1 HRP20180506TT HRP20180506T HRP20180506T1 HR P20180506 T1 HRP20180506 T1 HR P20180506T1 HR P20180506T T HRP20180506T T HR P20180506TT HR P20180506 T HRP20180506 T HR P20180506T HR P20180506 T1 HRP20180506 T1 HR P20180506T1
Authority
HR
Croatia
Prior art keywords
locus
meganuclease
human
artificial
cell
Prior art date
Application number
HRP20180506TT
Other languages
English (en)
Croatian (hr)
Inventor
Ronald Buelow
Original Assignee
Open Monoclonal Technology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40111008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180506(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Open Monoclonal Technology, Inc. filed Critical Open Monoclonal Technology, Inc.
Publication of HRP20180506T1 publication Critical patent/HRP20180506T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
HRP20180506TT 2007-06-01 2018-03-27 Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela HRP20180506T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94161907P 2007-06-01 2007-06-01
US4432408P 2008-04-11 2008-04-11
EP12187787.2A EP2602323B1 (en) 2007-06-01 2008-05-30 Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies

Publications (1)

Publication Number Publication Date
HRP20180506T1 true HRP20180506T1 (hr) 2018-05-04

Family

ID=40111008

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180506TT HRP20180506T1 (hr) 2007-06-01 2018-03-27 Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela

Country Status (21)

Country Link
US (6) US8703485B2 (enExample)
EP (4) EP3382022A1 (enExample)
JP (6) JP5823690B2 (enExample)
KR (4) KR101661357B1 (enExample)
CN (1) CN101784664B (enExample)
AT (1) ATE522611T1 (enExample)
AU (1) AU2008259939B2 (enExample)
CA (2) CA3054224A1 (enExample)
CY (1) CY1120383T1 (enExample)
DK (3) DK2602323T3 (enExample)
ES (3) ES2372718T3 (enExample)
HR (1) HRP20180506T1 (enExample)
HU (1) HUE037302T2 (enExample)
IL (2) IL202302A (enExample)
LT (1) LT2602323T (enExample)
NZ (1) NZ581396A (enExample)
PL (3) PL2602323T3 (enExample)
PT (3) PT2152880E (enExample)
SG (2) SG182144A1 (enExample)
SI (1) SI2602323T1 (enExample)
WO (1) WO2008151081A1 (enExample)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005263994B2 (en) 2004-07-22 2011-03-24 Roger Kingdon Craig Binding molecules
EP3382022A1 (en) * 2007-06-01 2018-10-03 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
CN102177235A (zh) * 2008-09-08 2011-09-07 赛莱克蒂斯公司 切割来自谷氨酰胺合成酶基因的dna靶序列的大范围核酸酶变体及其用途
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
CN102625655B (zh) 2008-12-04 2016-07-06 桑格摩生物科学股份有限公司 使用锌指核酸酶在大鼠中进行基因组编辑
US20110314563A1 (en) 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK2564695T3 (en) 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
JP5909449B2 (ja) 2009-12-10 2016-04-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 重鎖抗体を作製するマウス
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PL2505654T5 (pl) 2010-02-08 2020-11-30 Regeneron Pharmaceuticals, Inc. Mysz ze wspólnym łańcuchem lekkim
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL2553100T3 (pl) 2010-03-31 2018-03-30 Ablexis, Llc Inżynieria genetyczna zwierząt nie będących ludźmi w celu wytworzenia przeciwciał chimerycznych
EP3366125A1 (en) * 2010-06-17 2018-08-29 Kymab Limited Animal models and therapeutic molecules
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10881084B2 (en) 2010-07-26 2021-01-05 Trianni, Inc Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
CN108220297A (zh) 2011-03-09 2018-06-29 细胞信号科技公司 用于生成单克隆抗体的方法和试剂
BR112013025567B1 (pt) * 2011-04-27 2021-09-21 Amyris, Inc Métodos para modificação genômica
WO2013022782A1 (en) 2011-08-05 2013-02-14 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
IL277027B (en) 2011-09-21 2022-07-01 Sangamo Therapeutics Inc Methods and compositions for regulation of transgene expression
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
LT2627773T (lt) 2011-10-17 2017-12-27 Regeneron Pharmaceuticals, Inc. Pelės iškirpta sunkioji imunoglobulino grandinė
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
AU2013251558B2 (en) 2012-04-25 2019-01-03 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
PL2858487T3 (pl) 2012-06-12 2020-06-01 Regeneron Pharmaceuticals, Inc. Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny
JP6279562B2 (ja) * 2012-06-12 2018-02-14 ジェネンテック， インコーポレイテッド 条件付きノックアウト対立遺伝子を生成するための方法および組成物
FI3653049T3 (fi) * 2012-12-14 2023-11-02 Omniab Inc Polynukleotidit, jotka koodaavat jyrsijän vasta-aineita, joissa on ihmisen idiotyyppejä, ja näitä käsittävät eläimet
DK2840892T3 (en) 2013-02-20 2018-07-23 Regeneron Pharma Non-human animals with modified heavy chain immunoglobulin sequences
PL2967012T3 (pl) 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
HRP20181648T1 (hr) 2013-04-16 2019-01-25 Regeneron Pharmaceuticals, Inc. Ciljana modifikacija genoma štakora
US20160040155A1 (en) * 2013-04-16 2016-02-11 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
KR102846903B1 (ko) 2014-03-21 2025-08-20 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
US20150266976A1 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
SG11201608208VA (en) 2014-04-30 2016-11-29 Hanall Biopharma Co Ltd Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
CA2950173C (en) 2014-06-06 2023-10-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for modifying a targeted locus
KR102386101B1 (ko) 2014-06-26 2022-04-14 리제너론 파마슈티칼스 인코포레이티드 표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
EP3174902B1 (en) 2014-08-01 2019-04-17 Institut National de la Sante et de la Recherche Medicale (INSERM) An anti-cd45rc antibody for use as drug
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
CN107208113A (zh) 2014-12-19 2017-09-26 瑞泽恩制药公司 用于通过单步多重靶向进行靶向遗传修饰的方法和组合物
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP3277823B1 (en) * 2015-04-03 2023-09-13 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
DK3334763T3 (da) 2015-08-11 2024-10-07 Wuxi Biologics Ireland Ltd Nye anti-PD-1-antistoffer
IL257411B2 (en) * 2015-08-24 2024-05-01 Trianni Inc Enhanced production of immunoglobulins
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
IL260743B2 (en) 2016-02-04 2024-03-01 Trianni Inc Advanced production of antibodies
AU2017272337C1 (en) 2016-06-03 2024-02-29 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
KR20190052006A (ko) 2016-08-24 2019-05-15 테네오바이오, 인코포레이티드 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물
UA126384C2 (uk) 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
WO2018054241A1 (en) 2016-09-20 2018-03-29 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-pcsk9 antibodies
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
KR102706743B1 (ko) 2016-12-21 2024-09-19 세파론 엘엘씨 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도
KR20250004936A (ko) 2016-12-21 2025-01-08 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CA3050715A1 (en) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
KR102742528B1 (ko) 2017-06-20 2024-12-16 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
AU2018330180B2 (en) 2017-09-07 2025-07-17 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
CN111133007A (zh) 2017-09-13 2020-05-08 特尼奥生物股份有限公司 与胞外酶结合的重链抗体
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
UA128757C2 (uk) 2017-12-22 2024-10-16 Тенеобіо, Інк. Антитіла, які містять тільки важкі ланцюги, що зв'язуються з cd22
RU2020124623A (ru) 2017-12-27 2022-01-27 Тенеобио, Инк. Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон
DK3772927T3 (da) 2018-03-24 2025-02-17 Regeneron Pharma Genetisk modificerede mus eller rotter til generering af terapeutiske antistoffer mod peptid¿MHC-komplekser, fremgangsmåde til fremstilling og anvendelser deraf
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
US12428471B2 (en) * 2018-06-13 2025-09-30 Crystal Bioscience Inc. Transgenic chicken that makes antibodies with long CDR-H3S stabilized by multiple disulfide bridges and diversified by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CA3101069A1 (en) 2018-07-20 2020-01-23 Teneobio, Inc. Heavy chain antibodies binding to cd19
MX2021001305A (es) 2018-08-01 2021-06-23 Cephalon Inc Anticuerpos anti-cxcr2 y usos de los mismos.
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CN113614107A (zh) 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
CN117099741B (zh) 2019-02-18 2025-11-21 百奥赛图(北京)医药科技股份有限公司 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物
PE20220142A1 (es) 2019-04-05 2022-01-27 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
US20220251232A1 (en) 2019-05-20 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies
JOP20210323A1 (ar) 2019-06-14 2023-01-30 Teneobio Inc ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
WO2021058795A2 (en) 2019-09-27 2021-04-01 Stark Labs Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma mhc ii peptide protein structures and uses thereof
MX2022013453A (es) 2020-04-29 2022-11-16 Teneobio Inc Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
EP4158034A4 (en) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
US20240002521A1 (en) 2020-11-20 2024-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
EP4247497A1 (en) 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-cd25 antibodies
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CN118984837A (zh) 2022-01-28 2024-11-19 乔治穆内公司 作为pd-1激动剂的程序性细胞死亡蛋白1的抗体
KR20240155347A (ko) 2022-03-09 2024-10-28 알데란 바이오테크놀로지 항-cd160 막관통 동형 항체
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
WO2024062019A1 (en) 2022-09-21 2024-03-28 Synabs Anti-ccr8 antibodies and uses thereof
WO2025191147A1 (en) 2024-03-14 2025-09-18 Synabs Anti-ccr8 antibodies and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
AU8212291A (en) 1990-07-10 1992-02-04 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
DE4119749A1 (de) 1991-06-15 1992-12-17 Claas Ohg Verfahren zum entholzen von flachs und flachsaufbereitungsmaschine zur durchfuehrung dieses verfahrens
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
ATE420178T1 (de) 1992-08-21 2009-01-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5795974A (en) 1993-12-10 1998-08-18 University Of Utah Research Foundation Mycoplasma arthritidis superantigen
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
WO1997016537A1 (en) 1995-10-30 1997-05-09 Spectral Diagnostics, Inc. Stable chicken b-cell line and method of use thereof
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
CA2273194C (en) * 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6372956B1 (en) * 1998-12-31 2002-04-16 The J. David Gladstone Institutes Transgenic rats and rat cell lines expressing human CD4 and a human chemokine receptor
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
WO2001027279A1 (en) * 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use
JP2004500843A (ja) * 2000-04-24 2004-01-15 ワイエス トランスジェニック動物
NZ524523A (en) * 2000-08-03 2006-02-24 Therapeutic Human Polyclonals Production of humanized antibodies in transgenic animals
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1916303B1 (en) * 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1420637A4 (en) 2001-08-20 2005-11-30 Merck & Co Inc TRANSGENIC NOSES AS ANIMAL MODELS FOR THE MODULATION OF THE B1 BRADYKININ RECEPTOR PROTEIN
DE60236182D1 (de) * 2001-09-14 2010-06-10 Cellectis Zufällige integration von polynukleotide nach in vivo linearisierung
DK1461442T3 (en) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
ATE372379T1 (de) 2002-03-15 2007-09-15 Cellectis Hybride and einzelkettige meganukleasen und deren anwendungen
EP1504092B2 (en) * 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
US20060206949A1 (en) * 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
WO2004072115A2 (en) * 2003-02-05 2004-08-26 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
WO2005014650A2 (en) * 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20050153392A1 (en) * 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
WO2005038001A2 (en) * 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
US8137966B2 (en) 2004-03-04 2012-03-20 Dainippon Sumitomo Pharma Co., Ltd. Rat embryonic stem cell
AU2005263994B2 (en) 2004-07-22 2011-03-24 Roger Kingdon Craig Binding molecules
US20060130157A1 (en) * 2004-10-22 2006-06-15 Kevin Wells Ungulates with genetically modified immune systems
CA2584814A1 (en) * 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglobulin expression in non-human transgenic animals
EP1854473A1 (en) 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
EP2327773A1 (en) 2005-03-15 2011-06-01 Cellectis I-crel meganuclease variants with modified specificity, method of preparation and uses thereof
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007060495A1 (en) * 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
US7491866B2 (en) 2005-11-09 2009-02-17 Board Of Regents University Of Texas System Transgenic rats and spermatogonial stem cells
CA2638117A1 (en) 2006-01-25 2007-08-30 Erasmus University Medical Center Rotterdam Generation of heavy-chain only antibodies in transgenic animals
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP3382022A1 (en) * 2007-06-01 2018-10-03 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
DK2840892T3 (en) * 2013-02-20 2018-07-23 Regeneron Pharma Non-human animals with modified heavy chain immunoglobulin sequences

Also Published As

Publication number Publication date
US8703485B2 (en) 2014-04-22
EP2152880A4 (en) 2010-06-16
JP6220827B2 (ja) 2017-10-25
LT2602323T (lt) 2018-04-10
IL202302A (en) 2013-07-31
KR101661357B1 (ko) 2016-09-29
US20210253673A1 (en) 2021-08-19
JP2010529042A (ja) 2010-08-26
KR20180090395A (ko) 2018-08-10
US20190169270A1 (en) 2019-06-06
EP2152880B1 (en) 2011-08-31
IL220209A (en) 2013-11-28
HK1135138A1 (en) 2010-05-28
DK2602323T3 (en) 2018-04-16
WO2008151081A8 (en) 2010-02-04
CA2688834C (en) 2020-01-07
JP2022118217A (ja) 2022-08-12
WO2008151081A1 (en) 2008-12-11
IL220209A0 (en) 2012-07-31
KR102096731B1 (ko) 2020-04-02
JP6712254B2 (ja) 2020-06-17
KR20100037027A (ko) 2010-04-08
CN102850452A (zh) 2013-01-02
US9388233B2 (en) 2016-07-12
EP3382022A1 (en) 2018-10-03
PT2336329E (pt) 2012-12-24
ES2372718T3 (es) 2012-01-25
EP2602323A1 (en) 2013-06-12
ES2393826T3 (es) 2012-12-28
KR20170016518A (ko) 2017-02-13
SG182144A1 (en) 2012-07-30
CA2688834A1 (en) 2008-12-11
KR101886610B1 (ko) 2018-08-09
PL2336329T3 (pl) 2013-04-30
KR101703299B1 (ko) 2017-02-06
CA3054224A1 (en) 2008-12-11
CN101784664B (zh) 2013-04-10
US20090098134A1 (en) 2009-04-16
PL2602323T3 (pl) 2018-06-29
SG10201509853UA (en) 2015-12-30
SI2602323T1 (en) 2018-05-31
NZ581396A (en) 2012-07-27
ES2664218T3 (es) 2018-04-18
IL202302A0 (en) 2011-08-01
EP2602323B1 (en) 2018-02-28
JP2018000201A (ja) 2018-01-11
PL2152880T3 (pl) 2012-03-30
AU2008259939A1 (en) 2008-12-11
KR20150101475A (ko) 2015-09-03
EP2336329A1 (en) 2011-06-22
AU2008259939B2 (en) 2014-03-13
CN101784664A (zh) 2010-07-21
JP2014027947A (ja) 2014-02-13
DK2336329T3 (da) 2013-01-07
ATE522611T1 (de) 2011-09-15
PT2602323T (pt) 2018-04-02
US20160311888A1 (en) 2016-10-27
EP2152880A1 (en) 2010-02-17
US10072069B2 (en) 2018-09-11
PT2152880E (pt) 2011-12-15
HUE037302T2 (hu) 2018-08-28
CY1120383T1 (el) 2019-07-10
JP2020125360A (ja) 2020-08-20
EP2336329B8 (en) 2012-11-21
EP2336329B1 (en) 2012-10-10
US8907157B2 (en) 2014-12-09
DK2152880T3 (da) 2011-11-28
JP5823690B2 (ja) 2015-11-25
US20120090041A1 (en) 2012-04-12
US20100212035A1 (en) 2010-08-19
JP2015204840A (ja) 2015-11-19

Similar Documents

Publication Publication Date Title
HRP20180506T1 (hr) Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela
Kuroiwa et al. Cloned transchromosomic calves producing human immunoglobulin
Dyck et al. Making recombinant proteins in animals–different systems, different applications
Dimitrov et al. Germline gene editing in chickens by efficient CRISPR-mediated homologous recombination in primordial germ cells
Cooper et al. Innovative approaches to genome editing in avian species
CZ20032192A3 (en) Methods of modifying eukaryotic cells
BR112014026294B1 (pt) Método para modificar um lócus genômico alvo em uma célula tronco embrionária (es) de camundongo
CN111471719A (zh) 有效的非减数分裂等位基因渐渗
Doran et al. Advances in genetic engineering of the avian genome:“Realising the promise”
Tizard et al. Potential benefits of gene editing for the future of poultry farming
Liu et al. Efficient production of transgenic chickens based on piggyBac
CN109112159A (zh) 基于Cas9介导的定点整合FABP4基因和MSTN基因点突变打靶载体及重组细胞
CA2501415A1 (en) Method of selecting cells for somatic cell nuclear transfer
CN113646429B (zh) 敲入细胞的制作方法
CN106978416A (zh) 一种基因定位整合表达系统及其应用
JP7578306B2 (ja) 動物の製造方法
WO2022050377A1 (ja) 標的ｄｎａの編集方法、標的ｄｎａが編集された細胞の製造方法、及びそれらに用いるｄｎａ編集システム
Jones Genetic engineering of a mouse: Dr. Frank Ruddle and somatic cell genetics
Duncan et al. Chromosomal engineering
CN117643284B (zh) 一种kiaa1191基因不表达的异种移植供体猪及制备方法
CN116889215B (zh) 一种fndc1基因不表达的异种移植供体猪及制备方法
CN114606270B (zh) 一种Mia3条件性基因敲除小鼠模型的构建方法
Cyriac et al. Transgenic chicken: methods and applications.
RU2849189C1 (ru) Линия трансгенных мышей C57BL/6J-Tg(CMV-H2B-eGFP)12Ched, экспрессирующая флуоресцентно меченный гистон H2B в постнатальном возрасте, и способ ее получения
US20240090480A1 (en) Split-intein methods and compositions for generation of single sex offspring